Targeting CXCL13 During Neuroinflammation
Amanda K Huber1, David N Irani1
1Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
Advances in Neuroimmune Biology
|February 9, 2016
Summary
Chemokine CXCL13, crucial for lymphoid organs, also drives central nervous system (CNS) inflammation. Targeting CXCL13 or its receptor offers a potential therapeutic strategy for CNS disorders.
Area of Science:
- Neuroimmunology
- Molecular Biology
Background:
- Chemokine C-X-C motif ligand 13 (CXCL13) is essential for lymphocyte and antigen-presenting cell organization in lymphoid organs.
- CXCL13 is increasingly recognized for its role in central nervous system (CNS) inflammation.
Purpose of the Study:
- To review the contribution of CXCL13 to the pathogenesis of CNS disorders.
- To evaluate CXCL13 as a potential therapeutic target in CNS diseases.
Main Methods:
- Literature review of studies involving experimental animals and human subjects.
- Analysis of the role of CXCL13 and its receptor in CNS inflammation.
Main Results:
- CXCL13 plays a role in the pathogenesis of various CNS disorders, including neoplastic, infectious, and autoimmune conditions.
- Evidence suggests that blocking CXCL13 or its receptor may benefit patients with certain CNS diseases.
Conclusions:
- CXCL13 is implicated in CNS inflammation and disease pathogenesis.
- Therapeutic strategies targeting CXCL13, such as monoclonal antibodies or small molecule inhibitors, show promise for treating CNS disorders.
Keywords:
CXCL13CXCR5lymphoid chemokinesmultiple sclerosisneuroborreliosispost-stroke dementiaprimary central nervous system lymphoma
